Literature DB >> 27408357

Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon.

Władysław B Gaweł1, Grzegorz Helbig2, Kinga Boral2, Sławomira Kyrcz-Krzemień2.   

Abstract

Leukemic transformation in patients diagnosed with polycythemia vera (PV) is associated with poor prognosis and median survival not exceeding 3 months. To date only a few cases of post-PV acute lymphoblastic leukemia (ALL) have been reported. A 64-year-old female patient developed ALL 4 years after she had met PV criteria. At PV diagnosis a molecular study was positive for the JAK2V617F mutation. Due to high risk features (history of deep vein thrombosis) she was treated with hydroxyurea (HU) with moderate efficacy. She became anemic and thrombocytopenic with mild leukocytosis while still on HU. Blood and bone marrow smears revealed 40 and 100 % of blast cells, respectively. The immunophenotyping of blasts was consistent with a diagnosis of early precursor B cell ALL. She was found to be positive for the JAK2V617F mutation. Patient received an ALL induction regimen and achieved complete remission with negative minimal residual disease by flow cytometry. The post-chemotherapy study for the JAK2V617F mutation was positive. Patient has remained in remission for 4 months. A suitable donor searching was initiated. Post-PV ALL is an extremely rare phenomenon. Due to poor prognosis, an allogeneic stem cell transplantation should be considered in fit patients who achieved remission.

Entities:  

Keywords:  Acute lymphoblastic leukemia; JAK2V617F mutation; Leukemic transformation; Polycythemia vera

Year:  2016        PMID: 27408357      PMCID: PMC4925563          DOI: 10.1007/s12288-016-0673-z

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  18 in total

1.  Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.

Authors:  Maro Ohanian; Vasiliki Leventaki; Srdan Verstovsek; Zeev Estrov; Pei Lin; Cameron Yin; Hagop Kantarjian; Yang Huh; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2012-03-13

Review 2.  Acute lymphoid leukemia following polycythemia vera.

Authors:  M Camós; F Cervantes; S Montoto; J C Hernández-Boluda; N Villamor; E Montserrat
Journal:  Leuk Lymphoma       Date:  1999-01

3.  Lymphoblastic-like leukemic transformation of polycythemia vera.

Authors:  R Hoffman; S Estren; S Kopel; S M Marks; R P McCaffrey
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

4.  Terminal lymphoblastic transformation in polycythemia vera.

Authors:  T A Braich; T M Grogan; M J Hicks; B R Greenberg
Journal:  Am J Med       Date:  1986-02       Impact factor: 4.965

Review 5.  Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Authors:  Ayalew Tefferi; Tiziano Barbui
Journal:  Am J Hematol       Date:  2015-02       Impact factor: 10.047

6.  Polycythaemia rubra vera transforming to acute lymphoblastic leukaemia.

Authors:  R Aitchison; A J Black; M F Greaves
Journal:  Clin Lab Haematol       Date:  1987

7.  Acute lymphoblastic leukemia in a patient with longstanding polycythemia vera: cytogenetic analysis reveals two distinct abnormal clones.

Authors:  J Anastasi; M J Pettenati; M M Le Beau; H C Kwaan; S C Weil
Journal:  Am J Hematol       Date:  1988-09       Impact factor: 10.047

8.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

9.  Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia.

Authors:  A Polliack; M Prokocimer; Y Matzner
Journal:  Am J Hematol       Date:  1980       Impact factor: 10.047

Review 10.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.

Authors:  S Cerquozzi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.